Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.G M Brodeur, F Hedborg, Jon Pritchard et al.|Journal of Clinical Oncology|1993Cited by 2.3k
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH studyJoëlle Vermeulen, Jo Vandesompele, Nadine Van Roy et al.|The Lancet Oncology|2009Cited by 196
Two independent epigenetic biomarkers predict survival in neuroblastomaYania Yáñez, Victoria Castel, Elena Grau et al.|Clinical Epigenetics|2015Cited by 33
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens et al.|Journal of Clinical Oncology|2024Cited by 25
Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targetsEsther Coronado, Jaime Font de Mora, Enrique Vidal et al.|Molecular Oncology|2020Cited by 9